Derek O’Reilly

Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial

John P. Neoptolemos, Daniel H. Palmer, Paula Ghaneh et al. · The Lancet · 2017 · 1.9K citations · Full text

Optimal Duration and Timing of Adjuvant Chemotherapy After Definitive Surgery for Ductal Adenocarcinoma of the Pancreas: Ongoing Lessons From the ESPAC-3 Study

Juan W. Valle, Daniel H. Palmer, Richard Jackson et al. · Journal of Clinical Oncology · 2014 · 445 citations · Full text

Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial

John Primrose, Stephen Falk, Meg Finch-Jones et al. · The Lancet Oncology · 2014 · 421 citations

Systemic Chemotherapy, New Epoc, Surgical Oncology +10

Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial

Paula Ghaneh, Daniel H. Palmer, Silvia Cicconi et al. · ˜The œLancet. Gastroenterology & hepatology · 2022 · 294 citations · Full text

Surgical Oncology, Immediate Surgery, Pancreatic Cancer +7

Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma

Robert Jones, Eftychia‐Eirini Psarelli, Richard Jackson et al. · JAMA Surgery · 2019 · 256 citations · Full text